- Home
- CHMI vs PLRX Comparison
CHMI vs PLRX Comparison
Compare CHMI & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHMI | PLRX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 71.3M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CHMI | PLRX |
|---|---|---|
| Price | $2.62 | $1.13 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | $3.00 | ★ $3.75 |
| AVG Volume (30 Days) | 177.5K | ★ 877.1K |
| Earning Date | 03-05-2026 | 03-02-2026 |
| Dividend Yield | ★ 15.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $40,202,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $31.73 | N/A |
| P/E Ratio | $138.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.17 | $1.09 |
| 52 Week High | $3.68 | $3.78 |
Technical Indicators
Market Signals| Indicator | CHMI | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.23 | 37.89 |
| Support Level | $2.54 | $1.11 |
| Resistance Level | $2.63 | $1.22 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 12.00 | 20.45 |
Price Performance
Historical ComparisonAbout CHMI Cherry Hill Mortgage Investment Corporation
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.